Skip to Content

Darzalex Faspro Approval History

FDA Approved: Yes (First approved May 1, 2020)
Brand name: Darzalex Faspro
Generic name: daratumumab and hyaluronidase-fihj
Dosage form: Injection
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Multiple Myeloma

Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase indicated for the treatment of adult patients with multiple myeloma.

Development History and FDA Approval Process for Darzalex Faspro

DateArticle
May  2, 2020Approval FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide